Magnetar Financial LLC Boosts Stake in Amedisys, Inc. (NASDAQ:AMED)

Magnetar Financial LLC boosted its stake in Amedisys, Inc. (NASDAQ:AMED) by 0.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 637,443 shares of the health services provider’s stock after buying an additional 1,835 shares during the quarter. Amedisys makes up about 1.4% of Magnetar Financial LLC’s holdings, making the stock its 20th biggest position. Magnetar Financial LLC owned about 1.95% of Amedisys worth $57,873,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. National Bank of Canada FI lifted its stake in Amedisys by 119.0% in the 3rd quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock valued at $5,365,000 after buying an additional 30,213 shares in the last quarter. ABC Arbitrage SA purchased a new position in shares of Amedisys during the 4th quarter worth $2,522,000. Geode Capital Management LLC lifted its stake in shares of Amedisys by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after purchasing an additional 7,071 shares during the period. Quarry LP purchased a new position in shares of Amedisys during the 3rd quarter worth $2,569,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Amedisys by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock worth $33,400,000 after purchasing an additional 9,004 shares during the period. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Trading Up 0.4 %

Shares of AMED opened at $92.89 on Thursday. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $3.05 billion, a P/E ratio of 36.86, a price-to-earnings-growth ratio of 1.78 and a beta of 0.76. The stock’s fifty day simple moving average is $92.19 and its 200 day simple moving average is $92.67. Amedisys, Inc. has a twelve month low of $82.15 and a twelve month high of $98.95.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.09). The company had revenue of $598.05 million during the quarter, compared to analyst estimates of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. On average, equities research analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Stephens reissued an “equal weight” rating and set a $101.00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.